… trial of pembrolizumab in 29 patients with advanced bladder cancer patients whose tumors
expressed ≥1 % PD-L1, RR was 24 %, including three cases of CR [46]. Another anti-PD-L1 …

… PD-L1 status, detected by immunohistochemistry, is associated with clinical response and
mortality in patients treated with anti-PD-1/PD… of events for patients treated with anti-PD-1 from …

… predict patient response … PD-1 pathway in the tumor immune evasion, recent clinical
development and commercialization of PD-1 pathway inhibitors, the toxicities associated with PD-1 …

… and clinically useful information with respect to anti-PD-1 or antiPD-L1 treatment. Here, with
… of PD-1 or PD-L1 inhibitors in both patients with cancer that were PD-L1 positive and PDL1 …

… cancer types in patients treated with anti–PD-1 antibody was also notable. Although anti–PD-1 …
observed in many patients with non–small-cell lung cancer, melanoma, or renal-cell …

… of HPD in patients with cancer treated by anti-PD-1/PD-L1 … exists in a fraction of patients
treated with anti-PD-1/PD-L1. This … treating elderly patients (>65 years old) with anti-PD-1/PD-L1 …

… Nivolumab was the first anti-PD-1 antibody evaluated in cancer patients and has been …
antibody with high affinity to PD-1 that blocks binding of PD-1 to both PDL-1 and PDL-2, thereby …

… In addition, targeting PD-L1 has been associated with a significant … of cancer patients [7].
The purpose of the present review was to elucidate the role of PD-1/PD-L1 signaling in cancer, …

… target PD-1 or its ligand PD-L1 in patients with advanced cancer, … will open novel avenues
for cancer immunotherapy. … T cells following TCR engagement, PD-1 mostly restrains (but not …

… Recently, cancer immunotherapy targeting PD-1 or PD-L1 has proven effective in causing …
believe that PD-1/PD-L1 blockade therapy will be the major cancer immunotherapy method in …